82 related articles for article (PubMed ID: 17955490)
1. Production of P-glycoprotein from the MDR1 upstream promoter is insufficient to affect the response to first-line chemotherapy in advanced breast cancer.
Raguz S; Randle RA; Sharpe ER; Foekens JA; Sieuwerts AM; Meijer-van Gelder ME; Melo JV; Higgins CF; Yagüe E
Int J Cancer; 2008 Mar; 122(5):1058-67. PubMed ID: 17955490
[TBL] [Abstract][Full Text] [Related]
2. Activation of the MDR1 upstream promoter in breast carcinoma as a surrogate for metastatic invasion.
Raguz S; Tamburo De Bella M; Tripuraneni G; Slade MJ; Higgins CF; Coombes RC; Yagüe E
Clin Cancer Res; 2004 Apr; 10(8):2776-83. PubMed ID: 15102684
[TBL] [Abstract][Full Text] [Related]
3. Association of mdr1 gene expression with other prognostic factors and clinical outcome in human breast cancer.
Punyammalee B; Manoromana S; Purisa W; Chariyalertsak S; Rerkamnuaychok B
J Med Assoc Thai; 1997 Sep; 80 Suppl 1():S162-73. PubMed ID: 9347665
[TBL] [Abstract][Full Text] [Related]
4. New silicon compounds as resistance modifiers against multidrug-resistant cancer cells.
Molnar J; Mucsi I; Nacsa J; Hevér A; Gyémánt N; Ugocsai K; Hegyes P; Kiessig S; Gaal D; Lage H; Varga A
Anticancer Res; 2004; 24(2B):865-71. PubMed ID: 15161039
[TBL] [Abstract][Full Text] [Related]
5. Aberrant transcription from an unrelated promoter can result in MDR-1 expression following drug selection in vitro and in relapsed lymphoma samples.
Huff LM; Wang Z; Iglesias A; Fojo T; Lee JS
Cancer Res; 2005 Dec; 65(24):11694-703. PubMed ID: 16357181
[TBL] [Abstract][Full Text] [Related]
6. Negative regulation of MDR1 promoter activity in MCF-7, but not in multidrug resistant MCF-7/Adr, cells by cross-coupled NF-kappa B/p65 and c-Fos transcription factors and their interaction with the CAAT region.
Ogretmen B; Safa AR
Biochemistry; 1999 Feb; 38(7):2189-99. PubMed ID: 10026303
[TBL] [Abstract][Full Text] [Related]
7. Modulation of multidrug resistance gene expression in human breast cancer cells by (-)-gossypol-enriched cottonseed oil.
Ye W; Chang HL; Wang LS; Huang YW; Shu S; Dowd MK; Wan PJ; Sugimoto Y; Lin YC
Anticancer Res; 2007; 27(1A):107-16. PubMed ID: 17352222
[TBL] [Abstract][Full Text] [Related]
8. MDR1 gene expression in primary and advanced breast cancer.
Yang X; Uziely B; Groshen S; Lukas J; Israel V; Russell C; Dunnington G; Formenti S; Muggia F; Press MF
Lab Invest; 1999 Mar; 79(3):271-80. PubMed ID: 10092063
[TBL] [Abstract][Full Text] [Related]
9. Reversal of multidrug resistance by small interfering RNA (siRNA) in doxorubicin-resistant MCF-7 breast cancer cells.
Dönmez Y; Gündüz U
Biomed Pharmacother; 2011 Mar; 65(2):85-9. PubMed ID: 21237614
[TBL] [Abstract][Full Text] [Related]
10. Biological and clinical significance of concurrent p53 gene alterations, MDR1 gene expression, and S-phase fraction analyses in breast cancer patients treated with primary chemotherapy or radiotherapy.
Chevillard S; Lebeau J; Pouillart P; de Toma C; Beldjord C; Asselain B; Klijanienko J; Fourquet A; Magdelénat H; Vielh P
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2471-8. PubMed ID: 9815649
[TBL] [Abstract][Full Text] [Related]
11. Increased expression of sorcin is associated with multidrug resistance in leukemia cells via up-regulation of MDR1 expression through cAMP response element-binding protein.
Yamagishi N; Nakao R; Kondo R; Nishitsuji M; Saito Y; Kuga T; Hatayama T; Nakayama Y
Biochem Biophys Res Commun; 2014 Jun; 448(4):430-6. PubMed ID: 24796664
[TBL] [Abstract][Full Text] [Related]
12. Redundancy of biological regulation as the basis of emergence of multidrug resistance.
Shtil AA; Azare J
Int Rev Cytol; 2005; 246():1-29. PubMed ID: 16164965
[TBL] [Abstract][Full Text] [Related]
13. MDR1 (multidrug resistence 1) can regulate GCS (glucosylceramide synthase) in breast cancer cells.
Zhang X; Wu X; Li J; Sun Y; Gao P; Zhang C; Zhang H; Zhou G
J Surg Oncol; 2011 Oct; 104(5):466-71. PubMed ID: 21538359
[TBL] [Abstract][Full Text] [Related]
14. Altered methylation of the human MDR1 promoter is associated with acquired multidrug resistance.
Kantharidis P; El-Osta A; deSilva M; Wall DM; Hu XF; Slater A; Nadalin G; Parkin JD; Zalcberg JR
Clin Cancer Res; 1997 Nov; 3(11):2025-32. PubMed ID: 9815593
[TBL] [Abstract][Full Text] [Related]
15. Immunomagnetic purification of human breast carcinoma cells allows tumor-specific detection of multidrug resistance gene 1-mRNA by reverse transcriptase polymerase chain reaction in fine-needle aspirates.
Maas RA; Bruning PF; Breedijk AJ; Top B; Peterse HL
Lab Invest; 1995 Jun; 72(6):760-4. PubMed ID: 7540237
[TBL] [Abstract][Full Text] [Related]
16. Effect of MDR1 polymorphism on multidrug resistance expression in breast cancer patients.
Taheri M; Mahjoubi F; Omranipour R
Genet Mol Res; 2010 Jan; 9(1):34-40. PubMed ID: 20082268
[TBL] [Abstract][Full Text] [Related]
17. Reversal of drug resistance in breast carcinoma cells by anti-mdr1 ribozyme regulated by the tumor-specific MUC-1 promoter.
Gao P; Zhou GY; Guo LL; Zhang QH; Zhen JH; Fang AJ; Lin XY
Cancer Lett; 2007 Oct; 256(1):81-9. PubMed ID: 17637500
[TBL] [Abstract][Full Text] [Related]
18. Modulation of the typical multidrug resistance phenotype by targeting the MED-1 region of human MDR1 promoter.
Marthinet E; Divita G; Bernaud J; Rigal D; Baggetto LG
Gene Ther; 2000 Jul; 7(14):1224-33. PubMed ID: 10918491
[TBL] [Abstract][Full Text] [Related]
19. [Clinical significance of expression of multidrug resistance gene in breast cancer tissue].
Liu X; Song S; Shi C
Zhonghua Yi Xue Za Zhi; 1997 Jul; 77(7):488-90. PubMed ID: 9772445
[TBL] [Abstract][Full Text] [Related]
20. Reversal of multidrug resistance by two nordihydroguaiaretic acid derivatives, M4N and maltose-M3N, and their use in combination with doxorubicin or paclitaxel.
Chang CC; Liang YC; Klutz A; Hsu CI; Lin CF; Mold DE; Chou TC; Lee YC; Huang RC
Cancer Chemother Pharmacol; 2006 Nov; 58(5):640-53. PubMed ID: 16544145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
